bevacizumab
information and resources from the National Cancer Institute
bevacizumab
A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.bevacizumab
A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
|
|
|
|
news articles
Paclitaxel-Bevacizumab Combination Prolongs Progression-Free ... Mar 23, 2006
DG News NICE, FRANCE -- March 23, 2006 -- Patients with advanced breast cancer have a significantly longer progression-free survival when bevacizumab (Avastin) is ...
Paclitaxel combined with bevacizumab prolongs progression free ... Mar 23, 2006
Innovations-Report, Results from a large, randomised clinical trial for patients with breast cancer show that those who received bevacizumab (Avastin) in combination with ...
Should Some Cancer Drugs Be Given Sooner? Mar 29, 2006
KELOLAND TV, ...seeing patients responding so dramatically.". Two drugs are making the difference, Cetuximab and Bevacizumab. They're drugs with ...
Albert Szent-Gyorgyi Prize for Progress in Cancer Research Awarded ... Mar 31, 2006
Business Wire (press release), ..."Without Dr. Dvorak's fundamental discovery we would probably not have had the therapeutic agent bevacizumab which has had a tremendous impact on improving ...
Pro-Pharmaceuticals Completes Patient Enrollment in Stage 1 of ... Mar 30, 2006
Genetic Engineering News, ...product candidate, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (AVASTIN(R ...
Drug that opens a new front in the battle against breast cancer Mar 22, 2006
Times Online, Known generically as bevacizumab and manufactured by the pharmaceutical giant Roche, Avastin blocks the growth of new blood vessels that are needed for the ...
COMUNICADO: 90% of Cancer Patients Completely Unaware of New ... Mar 27, 2006
Europa Press, The first anti-angiogenic therapy, Avastin(R) (bevacizumab), was launched a year ago for the treatment of advanced colorectal cancer, and is the only anti ...
Most Patients Unaware of Breakthrough Drug That Could Reduce ... Mar 27, 2006
Halifax Live, The first anti-angiogenic therapy, Avastin (bevacizumab), was launched a year ago for the treatment of advanced colorectal cancer, and is the only anti ...
Updated Guidelines for Treatment of Ovarian Cancer Mar 27, 2006
Cancer Consultants (press release), The list of treatment options for recurrent ovarian cancer was broadened to include Arimidex® (anastrozole), Avastin® (bevacizumab), Camptosar® (ironotecan ...
Forecasts for the Approval of Several more Angiogenesis Inhibitors ... Mar 14, 2006
Business Wire (press release), The breakthrough came in 2004 when the FDA approved Genentechs bevacizumab (Avastin) for colon and rectum cancer and Eyetech Pharmaceuticals pegaptanib (Macugen ...
Drug can double breast cancer survival Mar 23, 2006
Daily Mail - UK, Avastin, also known as bevacizumab, has also been shown to work in a drug combination against colorectal cancer and to extend the life of people with lung ...
Avastin helps breast cancer patients: study Mar 22, 2006
Reuters Avastin, which is known generically as bevacizumab, has also been shown to work in a drug combination against colorectal cancer and to extend the life of ...
New Drugs Added to Breast Cancer Guidelines: Presented at NCCN Mar 13, 2006
DG News ...cancer guidelines by the National Comprehensive Cancer Network include numerous changes, including the addition of two new drugs -- bevacizumab and albumin ...
Pro-Pharmaceuticals' Abstract Accepted for Publication in ASCO ... Mar 17, 2006
International News Service, ...been conducting clinical and pre-clinical studies with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (AVASTIN(R ...
No Advantage With Thalidomide For Metastatic Renal Cell Carcinoma Mar 17, 2006
UroToday, They note that other antiangiogenic drugs, such as bevacizumab, sorafenib and sunitinib, "may have more promising activity in metastatic RCC.".
Targeted Agents Added to Guidelines for Non-Small Cell Lung Cancer ... Mar 20, 2006
DG News Maryland, United States. "But the most important change involved adding bevacizumab (Avastin) and erlotinib (Tarceva).". Although use ...
Drugs with Annual Sales Topping $1 Billion Accounted for ... Mar 21, 2006
PharmaLive.com (press release), Among the most important agents fitting this profile are Genentech's Avastin (bevacizumab) for various cancers, Neurochem's Alzhemed/Cerebril for Alzheimer's ...
Colorectal Cancer Patients Denied Life-Extending Treatment Mar 16, 2006
CNW Telbec (Communiqués de presse), Health Ministries in several provinces across the country have recently considered, and in some cases refused, funding for Avastin (bevacizumab), a targeted ...
Drugs added to cancer guidelines Mar 9, 2006
Monsters and Critics.com, ...and medicine at Johns Hopkins University School of Medicine in Baltimore, Md., 'but the most important change involved adding bevacizumab (Avastin) and ...
NCCN Announces Important Updates to Ovarian Cancer Clinical ... Mar 6, 2006
Genetic Engineering News, ...broadened the listing of acceptable recurrence modalities for ovarian cancer to include anastrazole (Arimidex, AstraZeneca), bevacizumab (Avastin, Genentech ...
ImClone’s Erbitux Receives FDA Label In Head And Neck Cancer Mar 2, 2006
BioWorld Online (subscription), Street. There’s also Avastin (bevacizumab), though that picture became clouded somewhat last month, when Genentech Inc. reported ...
New Therapies Target Cancer Mar 7, 2006
Drug Discovery & Development (subscription), Another monoclonal antibody, Avastin (bevacizumab), was approved as a first-line treatment for patients with metastatic colorectal cancer and was the first ...
Dendreon Reports Fourth Quarter and Year End 2005 Financial ... Mar 13, 2006
PR Newswire (press release), ...trial of PROVENGE in men with androgen-dependent prostate cancer; and -- Publish results from P-16 Phase 2 clinical trial of PROVENGE and bevacizumab in men ...
Avastin® Adriamycin Combination for Soft Tissue Sarcoma Mar 8, 2006
Cancer Consultants (press release), A multicenter trial has suggested that the addition of Avastin (bevacizumab) to Adriamycin (doxorubicin) improves outcomes of patients with metastatic soft ...
Rare brain condition to be added to Avastin label Mar 3, 2006
Pharma Times (subscription), ...about a rare brain condition called reversible posterior leukoencephalopathy to the label of their blockbuster cancer drug Avastin (bevacizumab), after a ...
Debate Over the Use of Anti-VEGF Therapy in Retinal Disease 21 Dec 2005
Medscape (subscription) AAO) Annual Meeting was dominated by discussions of the possible role of the anti-vascular endothelial growth factor (VEGF) agent bevacizumab in the therapy of ...
Letrozole-Bevacizumab Combination Safe and Effective in Women with ... Dec 9, 2005
DG News TX -- December 9, 2005 -- More than half of women with locally advanced breast cancer who were treated with letrozole in combination with bevacizumab showed a ...
Avastin®/Femara® Combination May Be Promising for Advanced ... Dec 20, 2005
Cancer Consultants (press release), Researchers from the Memorial Sloan-Kettering Cancer Center in New York recently reported that the treatment combination of Avastin (bevacizumab) and Femara ...
International Approvals: Retaane, Avelox, Generic Zinnat Dec 19, 2005
Medscape (subscription) The study will enroll patients with all forms of wet AMD who are being treated with intravitreal bevacizumab (Avastin, made by Genentech, Inc). ...
Heralded cancer drug a nimble weapon against other diseases Dec 18, 2005
Boston Globe, In 2004, the Food and Drug Administration approved the first angiogenesis inhibitor -- bevacizumab, or Avastin -- for the treatment of colon cancers. ...
Metronomic Therapy Appears Useful in Advanced Breast Cancer ... Dec 8, 2005
DG News SAN ANTONIO, TX -- December 8, 2005 -- Low-level, frequent-dosing treatment in combination with bevacizumab has potential benefits for some women with advanced ...
Plenary Session Snapshot Dec 19, 2005
Medscape (subscription) ...phosphorylase to generate 5-FU, preferentially within tumor tissue), and to assess the merits of targeted therapy such as Avastin (bevacizumab) in conjunction ...
OXiGENE to Commence First Ever Oncology Clinical Trial Combining a ... Dec 4, 2005
Finanzen.net, The Company will commence a PhaseIb clinical study to evaluate CA4P in combination therapy withAvastin(R) (Bevacizumab), a drug that is owned and marketed ...
OXiGENE to Commence First Ever Oncology Clinical Trial Combining a ... Dec 5, 2005
PR Newswire (press release), The Company will commence a Phase Ib clinical study to evaluate CA4P in combination therapy with Avastin(R) (Bevacizumab), a drug that is owned and marketed by ...
Low-dose chemotherapy plus antiangiogenesis drug has activity in ... Dec 8, 2005
EurekAlert (press release), In a pilot study of 55 patients, the combination of low-dose chemotherapy and the anti-VEGF antibody, bevacizumab (Avastin; Genentech) delayed the breast ...
Updated Results from Phase III Trial Evaluating Addition of ... Dec 9, 2005
Cancer Consultants (press release), ...the Eastern Cooperative Oncology Group (ECOG) recently reported updated results from the E2100 Trial in which the addition of Avastin (bevacizumab) to Taxol ...
Better Breast Cancer Treatment Dec 14, 2005
drkoop.com ...cancer. Instead of chemo, doctors gave her a combination of two drugs -- Herceptin (trastuzumab) and Avastin (bevacizumab). "Our ...
Hana Biosciences Announces Changes to Strengthen Management Team Dec 16, 2005
Business Wire (press release), Before joining Hana, Vitale led the Rituxan(R) (rituximab) commercial team and thought leader development for Avastin(R) (bevacizumab) at Genentech. ...
Top Advances in Cancer Treatment for 2005 Chosen by Oncologists Dec 2, 2005
SeniorJournal.com, 4. Bevacizumab (Avastin) improves lung cancer survival. A large ... 5. Bevacizumab (Avastin) improves colorectal cancer survival. A large ...
Monoclonal Antibody Combination Effective in Advanced Renal Cell ... Nov 29, 2005
Cancerpage.com, Twenty-five percent of 59 evaluable patients showed objective responses to treatment with bevacizumab and erlotinib, while another 61% had stable disease after ...
Molecular Advances Driving New Approaches in Colorectal Cancer ... Nov 18, 2005
DG News 12 th at the Oncology Nursing Society Institutes of Learning (ONS), Ms. Muehlbauer pointed to the monoclonal antibodies cetuximab and bevacizumab, the oral pro ...
Frequent, Low-Dose Chemo Fights Advanced Breast Cancer Dec 8, 2005
Forbes ...of 55 women found that the combination of low-dose chemotherapy -- a new strategy called "metronomic delivery" -- and Avastin (bevacizumab) delayed breast ...
New treatment for breast cancer studied Dec 8, 2005
United Press International ...study of 55 patients and found the combination of low-dose chemotherapy and the anti-vascular endothelial growth factor antibody bevacizumab (Avastin) delayed ...
SABCS: Low-dose Frequent Chemotherapy Plus Avastin Shows Activity ... Dec 9, 2005
MedPage Today, ...low doses given frequently shows activity in advanced breast cancer when it is given with the angiogenesis inhibitor Avastin (bevacizumab), investigators said ...
NCCN Announces Two New Breast Cancer Resources Dec 6, 2005
Business Wire (press release), For metastatic disease, new regimens including paclitaxel (Taxol) plus bevacizumab (Avastin) and albumin-bound paclitaxel (Abraxane) were added to the existing ...
Pro-Pharmaceuticals Announces Two International Clinical Sites in ... Dec 13, 2005
Genetic Engineering News, ...been conducting pre-clinical and clinical studies with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and bevacizumab (AVASTIN(R ...
OXiGENE Receives Regulatory Clearance to Commence Phase III ... Dec 12, 2005
Genetic Engineering News, ...paclitaxel for the treatment of platinum-resistant ovarian cancer, as well as a Phase Ib trial studying CA4P in combination with Avastin(R) (Bevacizumab). ...
Cancer Treatment Market for VEGF Inhibitors to Reach $5.3 Billion ... Nov 29, 2005
SeniorJournal.com, ...this market will be fueled by increased sales of the only currently- available cancer drug in this class -- Genentech/Roche's Avastin (bevacizumab) -- as well ...
Dr. David Spigel Presenting at ASCO Gastrointestinal Symposium ... Dec 5, 2005
PharmaLive.com (press release), ..."Phase II Study of FOLFOX4, Bevacizumab and Erlotinib, as First-Line Therapy in Patients with Advanced Colorectal Cancer" will be presented as a poster on ...
Top cancer advances of 2005 Dec 5, 2005
Health24.com, ...resolve the debate," Horning said. Avastin (bevacizumab) fights advanced lung and colon cancers. This "angiogenesis inhibitor" drug ...
Cancer Treatment Market for Vascular Endothelial Growth Factor ... Nov 29, 2005
PR Newswire (press release), ...in this market will be fueled by increased sales of the only currently- available drug in this class -- Genentech/Roche's Avastin (bevacizumab) -- as well as ...
Xeloda®/Eloxatin®/Avastin® (XeloxA) Highly Active in Newly ... Nov 18, 2005
Cancer Consultants (press release), ...with metastatic colorectal cancer following treatment with treatment with Xeloda (capecitabine) and Eloxatin (oxapliatin) and Avastin (bevacizumab), termed the ...
|
|
